When the Smoke Clears, Relaxation Disappears

Fatal Forty DDI: cyclobenzaprine, smoked tobacco, CYP1A2
  • Avinash Ramchandani
  • Julio A. Gonzalez-Sotomayor

Abstract

This case discusses the pharmacokinetic interaction between cyclobenzaprine and smoked tobacco resulting in cyclobenzaprine toxicity due to reversal of enzyme induction. Cyclobenzaprine is a cytochrome P450 1A2 substrate. Smoked tobacco is a 1A2 inducer.

Keywords

Pharmacokinetic Induction Inducer CYP1A2 Cytochrome P450 1A2 Tobacco Smoked tobacco Smoking Polycyclic aromatic hydrocarbons Cyclobenzaprine Flexeril 

References

  1. 1.
    Wang RW, Liu L, Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996;24(7):786–91.PubMedGoogle Scholar
  2. 2.
    Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs. 2009;18(11):1533–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76:178–84.PubMedCrossRefGoogle Scholar
  4. 4.
    Chabria SB. Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity. J Occup Med Toxicol. 2006;1:16.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Spiller HA, Winter ML, Mann KV, et al. Five-year multicenter retrospective review of cyclobenzaprine toxicity. J Emerg Med. 1995;13(6):781–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Avinash Ramchandani
    • 1
  • Julio A. Gonzalez-Sotomayor
    • 2
  1. 1.Pain Care PhysiciansAustinUSA
  2. 2.Pain Division, Department of Anesthesiology and Perioperative MedicineOregon Health and Science UniversityPortlandUSA

Personalised recommendations